Previous 10 | Next 10 |
PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that...
PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, ...
Oyster Point Pharma (NASDAQ:OYST) announces its addition to Nasdaq Biotechnology Index, effective prior to market open on Dec. 20, 2021. It's a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapie...
PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that...
PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, ...
PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ...
PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced mult...
Oyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Conference Call November 4, 2021, 04:30 PM ET Company Participants Daniel Lochner - CFO Jeffrey Nau - President, CEO & Director John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Joe Catanzaro - ...
Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q3 2021 Earnings Call Nov 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q3 2021 Earnings Call Transcript...
Oyster Point Pharma (NASDAQ:OYST): Q3 GAAP EPS of -$0.68 beats by $0.48. Revenue of $17.94M Press Release As of September 30, 2021, cash and cash equivalents were $184.2M, compared to $192.6M as of December 31, 2020. For further details see: Oyster Point Pharma EPS beats by $0.48 ...
News, Short Squeeze, Breakout and More Instantly...
Oyster Point Pharma Inc. Company Name:
OYST Stock Symbol:
NASDAQ Market:
Oyster Point Pharma Inc. Website:
TYRVAYA ® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3 ’ 22 Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care Profes...
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...